Literature DB >> 22199327

Carbonic anhydrase IX, hypoxia-inducible factor-1α, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors.

Eija A Korkeila1, Jari Sundström, Seppo Pyrhönen, Kari Syrjänen.   

Abstract

Strong expression of carbonic anhydrase IX (CAIX), hypoxia-inducible factor-1α (HIF-1α), ezrin and glucose transporter-1 (GLUT-1) was previously shown to be related to adverse disease outcome in rectal cancer. In this study, operative samples of 178 rectal cancer patients 77 treated with short-course and 47 with long-course preoperative radiotherapy (RT), and 54 with no preoperative treatment, as well as 80 preoperative biopsies from the RT group patients were analyzed for these markers. For data reduction, principal component analysis (PCA) was used to extract a set of factors from the original clinicopathological variables that would explain as much as possible of their variance. After extraction and promax rotation, this set of five first-order factors (F1-F5) was used in multivariate (Cox) modeling together with the four biomarkers. In model 1 (biomarkers in operative samples), F1 was the only independent determinant of disease-free (DFS) (p=0.043) and disease-specific survival (DSS) (p=0.029). In model 2 (biomarkers in preoperative biopsies), none of the five factors or biomarkers were significantly associated with DFS. However, HIF-1α (p=0.024), ezrin (p=0.034), F1 (p=0.011), and F3 (p=0.001) were significant independent predictors of DSS. Similarly, in model 3 (ezrin in preoperative biopsies and others in operative samples), none of the factors or biomarkers were significant predictors of DFS. However, CAIX (p=0.028), and F1 (p= 0.017) were significantly associated with DSS. Preoperative RT markedly modifies the expression of these four biomarkers and also interferes with the original clinicopathological prognosticators (loaded to F1-F5), emphasizing the complexity of prognostication in rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22199327

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status.

Authors:  Songmi Noh; Ji-Ye Kim; Ja Seung Koo
Journal:  Tumour Biol       Date:  2014-05-22

2.  Angiogenic regeneration defines loco-regional recurrence following pre-operative radio-chemotherapy for rectal cancer: a pilot study.

Authors:  Michael I Koukourakis; Ioannis M Koukourakis; Stella Arelaki; Maria Kouroupi; Spyros Domoxoudis; Alexandra Giatromanolaki
Journal:  Mol Biol Rep       Date:  2019-02-05       Impact factor: 2.316

Review 3.  Nanoparticle-mediated targeted drug delivery for breast cancer treatment.

Authors:  Piumi Y Liyanage; Sajini D Hettiarachchi; Yiqun Zhou; Allal Ouhtit; Elif S Seven; Cagri Y Oztan; Emrah Celik; Roger M Leblanc
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

4.  Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease.

Authors:  Xochitl C Morgan; Boyko Kabakchiev; Levi Waldron; Andrea D Tyler; Timothy L Tickle; Raquel Milgrom; Joanne M Stempak; Dirk Gevers; Ramnik J Xavier; Mark S Silverberg; Curtis Huttenhower
Journal:  Genome Biol       Date:  2015-04-08       Impact factor: 13.583

5.  Association of Ezrin expression with the progression and prognosis of gastrointestinal cancer: a meta-analysis.

Authors:  Feng Liang; Yangxin Wang; Ligen Shi; Jianmin Zhang
Journal:  Oncotarget       Date:  2017-10-04

6.  GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer.

Authors:  Jing Yang; Jing Wen; Tian Tian; Zhongsheng Lu; Yao Wang; Zikai Wang; Xiangdong Wang; Yunsheng Yang
Journal:  Oncotarget       Date:  2017-02-14

7.  Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis.

Authors:  Zhigang Chen; Xin He; Wenjie Xia; Qi Huang; Zhigang Zhang; Jun Ye; Chao Ni; Pin Wu; Dang Wu; Jinghong Xu; Fuming Qiu; Jian Huang
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

8.  Oxygen-carbon nanotubes as a chemotherapy sensitizer for paclitaxel in breast cancer treatment.

Authors:  Yongkun Wang; Chuanying Wang; Yijun Jia; Xianhua Cheng; Qing Lin; Mingjie Zhu; Yunshu Lu; Longlong Ding; Ziyi Weng; Kejin Wu
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

9.  Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy.

Authors:  Naoki Sakuyama; Motohiro Kojima; Shingo Kawano; Yoko Matsuda; Mari Mino-Kenudson; Atsushi Ochiai; Masaaki Ito
Journal:  Cancer Sci       Date:  2018-03       Impact factor: 6.716

10.  Immunohistochemical Study of Ezrin Expression in Colorectal Carcinoma: A Comparative Study between Objective Method and Digital Quantitative Assessment.

Authors:  Essam E Ayad; Yousra O Kamal Eldin; Ali A El-Hindawi; Mona S Abdelmagid; Hesham A Elmeligy
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.